Q-omics provides the consensus-scored CDC6 profile across patient tissues and cancer cell-line models. CDC6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CDC6 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CDC6 RNA expression shows 25,764 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where CDC6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC6 survival associations across molecular data types. CDC6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC6 RNA expression–survival associations across cancer types. High CDC6 expression shows unfavorable associations in ACC, KIRP, MESO, KICH, LIHC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CDC6 RNA expression.
This table summarizes CDC6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CDC6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC6 shows higher tumor expression in HNSC, LUAD, BLCA, KIRP, COAD and KIRC. The HNSC box plot shows higher CDC6 RNA expression in tumor versus normal tissue (log2 FC = +2.188, t-test p < 0.001).
This table shows molecular features associated with CDC6 in patient tissues and cancer cell lines. In patient samples, CDC6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
